Erratum: Evaluation of the short-term efficacy of NSAIDs on patients with active ankylosing spondylitis in daily practice: A 3-month, longitudinal, observational study (Rheumatology International (2010) 30 (331-340) DOI 10.1007/s00296-009-0963-y);Evaluation of the short-term efficacy of NSAIDs on patients with active ankylosing spondylitis in daily practice: A 3-month, longitudinal, observational study

Rheumatology International

Volumn 30, Issue 3, 2010, Pages 331-340

  Cinar, Muhammet ^a   Dinc, Ayhan ^a   Simsek, Ismail ^a   Erdem, Hakan ^a   Koc, Bayram ^a   Pay, Salih ^a   Kilic, Selim ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Ankylosing spondylitis; Non steroidal anti inflammatory drugs; Therapy

Indexed keywords

ACEMETACIN; DICLOFENAC; FLURBIPROFEN; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANKYLOSING SPONDYLITIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE DURATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL METHOD; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 73649131606     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-010-1385-6     Document Type: Erratum

References (42)

1. A Anandarajah CT Ritchlin 2005 Treatment update on Spondyloarthropathy Curr Opin Rheumatol 17 247 256 10.1097/01.bor.0000159926.42761.dd 10.1097/01.bor.0000159926.42761.dd 15838232 (Pubitemid 40626775)
2. M Dougados 1990 Diagnosis and monitoring of spondylarthropathy Compr Ther 16 52 56 1:STN:280:DyaK3c3kt1KhsQ%3D%3D 2185916
3. I Gossec D van der Heijde A Melian, et al. 2005 Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis Ann Rheum Dis 64 1563 1567 10.1136/ard.2004.029611 10.1136/ard.2004.029611 1:CAS:528:DC%2BD2MXht1eksrjN 15731291 (Pubitemid 41532038)
4. J Braun J Sieper 2006 Spondylarthritides Z Rheumatol 65 7 613 632 10.1007/s00393-006-0116-6 10.1007/s00393-006-0116-6 1:STN:280: DC%2BD2svitlGrug%3D%3D 17072572 (Pubitemid 44900166)
5. M Dougados JM Béhier I Jolchine, et al. 2001 Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor in the treatment of ankylosing spondylitis. A six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug Arthritis Rheum 44 1 180 185 10.1002/1529-0131(200101)44:1<180::AID-ANR24>3.0.CO;2-K 10.1002/1529-0131(200101)44:1<180::AID-ANR24>3.0.CO;2-K 1:CAS:528:DC%2BD3MXht1yiurs%3D 11212158 (Pubitemid 32113133)
6. M Dougados A Gueguen JP Nakache, et al. 1999 Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial Rheumatology 38 235 244 10.1093/rheumatology/38.3.235 10.1093/rheumatology/38.3.235 1:STN:280: DyaK1M3lsFWnsw%3D%3D 10325662 (Pubitemid 29507159)
7. A Wanders D van der Heijde R Landewe, et al. 2005 Inhibition of radiographic progression in ankylosing spondylitis (AS) by continuous use of NSAIDs Arthritis Rheum 52 1756 1765 10.1002/art.21054 10.1002/art.21054 1:CAS:528:DC%2BD2MXlvFChurw%3D 15934081 (Pubitemid 40852884)
8. M Dougados B Dijkmans M Khan, et al. 2002 Conventional treatments for ankylosing spondylitis Ann Rheum Dis 61 40 50
9. MD Cohen 2004 Raising expectations for arthritis treatment. Biologic response modifiers are making remission possible Postgrad Med 116 5 41 42 10.3810/pgm.2004.11.1611 15580919
10. J Braun J Brandt J Listing, et al. 2002 Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial Lancet 359 1187 1193 10.1016/S0140-6736(02)08215-6 10.1016/S0140-6736(02)08215-6 1:CAS:528:DC%2BD38XivVShsro%3D 11955536 (Pubitemid 34304258)
11. J Brandt A Khariouzov J Listing, et al. 2003 Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis Arthritis Rheum 48 6 1667 1675 10.1002/art.11017 10.1002/art.11017 1:CAS:528:DC%2BD3sXltlSgu70%3D 12794835 (Pubitemid 36682375)
12. J Braun T Pham J Sieper (ASAS Working Group), et al. 2003 International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis Ann Rheum Dis 62 817 824 10.1136/ard.62.9.817 10.1136/ard.62.9.817 1:CAS:528:DC%2BD3sXns1SisLg%3D 12922952 (Pubitemid 37026490)
13. J Braun J Davis M Dougados (ASAS Working Group), et al. 2006 First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis Ann Rheum Dis 65 3 316 320 10.1136/ard.2005.040758 10.1136/ard.2005.040758 1:CAS:528:DC%2BD28XisFCjt7k%3D 16096329 (Pubitemid 43268219)
14. M Rudwaleit J Listing J Brandt, et al. 2004 Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis Ann Rheum Dis 63 6 665 670 10.1136/ard.2003.016386 10.1136/ard.2003.016386 1:CAS:528:DC%2BD2cXltFekurY%3D 15037444 (Pubitemid 38658395)
15. S van der Linden HA Valkenburg A Cats 1984 Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria Arthritis Rheum 27 4 361 368 10.1002/art.1780270401 10.1002/art.1780270401 6231933
16. S Garrett T Jenkinson LG Kennedy, et al. 1994 A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index J Rheumatol 21 12 2286 2291 1:STN:280: DyaK2M3htl2qsQ%3D%3D 7699630
17. A Calin S Garrett H Whitelock, et al. 1994 A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index J Rheumatol 21 12 2281 2285 1:STN:280:DyaK2M3htl2qsA%3D%3D 7699629
18. TR Jenkinson PA Mallorie HC Whitelock, et al. 1994 Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index J Rheumatol 21 9 1694 1698 1:STN:280:DyaK2M%2Fpslaquw%3D%3D 7799351
19. SD Jones A Steiner SL Garrett, et al. 1996 The Bath Ankylosing Spondylitis Patient Global Score (BAS-G) Br J Rheumatol 35 1 66 71 10.1093/rheumatology/35.1.66 10.1093/rheumatology/35.1.66 1:STN:280: DyaK283gt1Kiug%3D%3D 8624626
20. L Heuft-Dorenbosch A Spoorenberg A van Tubergen, et al. 2003 Assessment of enthesitis in ankylosing spondylitis Ann Rheum Dis 62 2 127 132 10.1136/ard.62.2.127 10.1136/ard.62.2.127 1:STN:280:DC%2BD3s%2FktlCqsQ%3D%3D 12525381 (Pubitemid 36135387)
21. MW Stewart DG Palmer RG Knight 1990 A self-report articular index measure of arthritic activity: investigations of reliability, validity and sensitivity J Rheumatol 17 8 1011 1015 1:STN:280:DyaK3M%2Fht1Chuw%3D%3D 2213775
22. Khan MA (2003) Clinical features of ankylosing spondylitis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weicman ME (eds) Rheumatology, 3rd edn. Mosby, Spain, pp 1161-1181
23. J Zochling J Braun 2005 Management and treatment of ankylosing spondylitis Curr Opin Rheumatol 17 4 418 425 10.1097/01.bor.0000163194.48723.64 10.1097/01.bor.0000163194.48723.64 1:CAS:528:DC%2BD2MXlt1Sms74%3D 15956838 (Pubitemid 41058401)
24. JJ Anderson G Baron D van der Heijde, et al. 2001 Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis Arthritis Rheum 44 8 1876 1886 10.1002/1529-0131(200108)44: 8<1876::AID-ART326>3.0.CO;2-F 10.1002/1529-0131(200108)44:8<1876::AID- ART326>3.0.CO;2-F 1:STN:280:DC%2BD3MvmtlGntw%3D%3D 11508441 (Pubitemid 32758236)
25. M Dougados 2001 Treatment of spondyloarthropathies. Recent advances and prospects in 2001 Joint Bone Spine 68 6 557 563 10.1016/S1297-319X(01)00328-1 10.1016/S1297-319X(01)00328-1 1:STN:280:DC%2BD38%2Fot1GnsA%3D%3D 11808999 (Pubitemid 34037292)
26. M Dougados M Revel MA Khan 1998 Spondylarthropathy treatment: progress in medical treatment, physical therapy and rehabilitation Baillieres Clin Rheumatol 12 4 717 736 10.1016/S0950-3579(98)80046-0 10.1016/S0950-3579(98) 80046-0 1:STN:280:DyaK1M7islCltw%3D%3D 9928504
27. M Dougados M Nguyen R Caporal, et al. 1994 Ximoprofen in ankylosing spondylitis. A double blind placebo controlled dose ranging study Scand J Rheumatol 23 5 243 248 10.3109/03009749409103723 10.3109/03009749409103723 1:STN:280:DyaK2M%2FmtlOnsQ%3D%3D 7973477
28. I Jajic A Nekora HA Chadri 1982 Pirprofen, indomethacin and placebo in ankylosing spondylitis. Double-blind comparison Nouv Presse Med 11 33 2491 2493 1:STN:280:DyaL3s%2FjvVGluw%3D%3D 6752873
29. RD Sturrock FD Hart 1974 Double-blind cross-over comparison of indomethacin, flurbiprofen, and placebo in ankylosing spondylitis Ann Rheum Dis 33 2 129 131 10.1136/ard.33.2.129 10.1136/ard.33.2.129 1:STN:280: DyaE2c7ktVWksA%3D%3D 4595274
30. E Batlle-Gualda M Figueroa J Ivorra, et al. 1996 The efficacy and tolerability of aceclofenac in the treatment of patients with ankylosing spondylitis: a multicenter controlled clinical trial. Aceclofenac Indomethacin Study Group J Rheumatol 23 7 1200 1206 1:CAS:528:DyaK28XkvFWmur4%3D 8823693
31. A Calin L Edmunds LG Kennedy 1993 Fatigue in ankylosing spondylitis-why is it ignored? J Rheumatol 20 6 991 995 1:STN:280:DyaK3szltlGjsw%3D%3D 8350337
32. E Dernis-Labous M Messow M Dougados 2003 Assessment of fatigue in the management of patients with ankylosing spondylitis Rheumatology (Oxford) 42 12 1523 1528 10.1093/rheumatology/keg421 10.1093/rheumatology/keg421 1:STN:280:DC%2BD3srntFyhsQ%3D%3D (Pubitemid 37508927)
33. J Zochling MH Bohl-Buhler X Baraliakos, et al. 2006 Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis-a population-based survey Clin Rheumatol 25 6 794 800 10.1007/s10067-005-0132-y 10.1007/s10067-005-0132-y 16528455 (Pubitemid 44473141)
34. J Zochling D van der Heijde R Burgos-Vargas, et al. 2006 Assessment in AS' international working group; European League Against Rheumatism. ASAS/EULAR recommendations for the management of ankylosing spondylitis Ann Rheum Dis 65 4 442 452 10.1136/ard.2005.041137 10.1136/ard.2005.041137 1:STN:280: DC%2BD287ktFGqsg%3D%3D 16126791
35. JC Davis Jr D Van Der Heijde J Braun, et al. 2003 Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial Arthritis Rheum 48 11 3230 3236 10.1002/art.11325 10.1002/art.11325 1:CAS:528:DC%2BD3sXpvVygtb0%3D 14613288 (Pubitemid 37409337)
36. JD Gorman KE Sack JC Davis Jr 2002 Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha N Engl J Med 346 18 1349 1356 10.1056/NEJMoa012664 10.1056/NEJMoa012664 1:CAS:528:DC%2BD38Xjt1Shs70%3D 11986408 (Pubitemid 34754607)
37. D van der Heijde A Kivitz MH Schiff (ATLAS Study Group), et al. 2006 Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial Arthritis Rheum 54 7 2136 2146 10.1002/art.21913 10.1002/art.21913 16802350 (Pubitemid 44051069)
38. KL Hyrich KD Watson AJ Silman, et al. 2006 Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register Rheumatology (Oxford) 45 12 1558 1565 10.1093/rheumatology/kel149 10.1093/rheumatology/kel149 1:CAS:528:DC%2BD28Xht1Kns73E (Pubitemid 44817065)
39. EK Gunal FO Sarvan S Kamali, et al. 2008 Low frequency of HLA-B27 in ankylosing spondylitis patients from Turkey Joint Bone Spine 75 3 299 302 10.1016/j.jbspin.2007.06.021 10.1016/j.jbspin.2007.06.021 18424159
40. M Cinar A Dinc I Simsek, et al. 2008 The rate and significance of Mediterranean fever gene mutations in patients with ankylosing spondylitis: a three-month, longitudinal clinical study Rheumatol Int 29 1 37 42 10.1007/s00296-008-0637-1 10.1007/s00296-008-0637-1 18597091
41. O Oniankitan N Ranaivo L Carton, et al. 2005 Poorly and well controlled spondyloarthropathies: a comparison of 2 groups of patients J Rheumatol 32 1 77 79 15630729
42. PG Hardo DM Chalmers M Jakeways, et al. 1993 Management of NSAIDs-related dyspepsia in the community Br J Clin Pract 47 5 241 242 1:STN:280: DyaK2c7it1Sgug%3D%3D 8292467